References
- Weinstock M. A., Norm J. W. Mycosis fungoides in the United States Increasing incidence and descriptive epidemiology. JAMA 1988; 260: 42–46
- Harris N. L., Jaffe E. S., Stein H., Banks P. M., Chan J. K. C., Cleary M. L., Delsol G., DeWolf-Peeters C., Falini B., Gatter K. C., et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–-1392
- Kuzel T. M., Roengik H. H., Jr, Rosen S. T. Mycosis fungoides and the Sezary syndrome: A review of pathogenesis, diagnosis, and therapy. Journal of Clinical Oncology 1991; 9: 1298–1313
- Kaye F. J., Bunn P. A., Jr, Steinberg S. M. A randomized trial comparing combination electronic-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine 1989; 321: 1784–1790
- Grever M. R., Bisaccia E., Scarborough D. A., Metz E. N., Neidhart J. A. An investigation of 2-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 1983; 61: 279–282
- Dang-Vu A. P., Olsen E. A., Vollmer R. T., Greenberg M. L., Hershfield M. S. Treatment of cutaneous T-cell lymphoma with 2-deoxycoformycin (Pentostatin). Journal of the American Academy of Dermatology 1988; 19: 692–698
- Cummins F. J., Kim K., Neiman R. S., Comis R. L., Oken M. M., Weitzman S. A., Mann R. B., O'Connell M. J. Phase II trial of Pentostatin in refractory lymphomas and cutaneous T-cell disease. Journal of Clinical Oncology 1991; 9: 565–571
- Von Hoff D. D., Dahlberg S., Hartstock R. J., Eyre H. J. Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: A Southwestern Oncology Clinical Group study. Journal of the National Cancer Institute 1990; 82: 1353–1355
- Tallman M. S., Hakimian D. Purine nucleoside analogs: Emerging roles in indolent lymphoproliferative disorders. Blood 1995; 86: 2463–2474
- Carson D. A., Wasson D. B., Taetle R., Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62: 737–743
- Tallman M. S., Hakimian D., Variakojis D., Koslow D., Sisney G. A., Rademaker A. W., Rose E., Kaul K. A single cycles of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992; 80: 2203–2209
- Piro L. D., Carrera C. J., Beutler E., Carson D. A. 2-Cholordeoxyadenosine: An effective new agent for the treatment of chromic lymphocytic leukemia. Blood 1988; 72: 1069–1073
- Hoffman M., Tallman M. S., Hakimian D., Janson D., Hogan D., Variakojis D., Kuzel T., Gordon L. I., Rai K. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. Journal of Clinical Oncology 1994; 12: 788–792
- Bunn P. A., Jr, Lamberg S. I. Report of the Committee on Staging and Classification of Cutaneous T-cell Lymphomas. Cancer Treatment Reports 1979; 63: 725–728
- Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Research 1971; 31: 1860–1861
- Liliemark J., Juliusson G. 2-Chloro-2-deoxyadenosine-clinical, biochemical and pharmacokinetic considerations. Archivum Immunologiae et Therapiae Experimentalis 1994; 42: 7–10
- Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. Journal of American Slat Association 1958; 53: 457–481
- Rosner B. Fundamentals of Biostatics4th ed. Duxburg Press, Belmont, CA 1993; 370: 372
- Kuzel T. M., Hurria A., Samuelson E., Tallman M. S., Roenigk H. H., Jr, Rademaker A. W., Rosen S. T. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 1996; 87: 906–911
- Saven A., Carrera C. J., Carson D. A., Beutler E., Piro L. D. 2-chlorodeoxyadenosine: An active agent in the treatment of cutaneous T-cell lymphoma. Blood 1992; 80: 587–592
- O'Brien S., Kurzrock R., Duvic M., Kantarjian H., Stass S., Robertson L. E., Estey E., Pierce S., Keating M. J. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 1994; 84: 733–738
- Betticher D. C., Fey M. F., von Rohr A., Tobler A., Jenzer H., Gratwohl A., Lohri A., Pugin P., Hess U., Pagani O., et al. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Annals of Oncology 1994; 5: 57–64
- Juliusson G., Christiansen I., Hansen M. M., Johnson S., Kimby E., Elmhorn-Rosenborg A., Liliemark J. Oral cladrihine as primary therapy for patients with B-cell chronic lymphocytic leukemia. Journal of Clinical Oncology 1996; 14: 2160–2166